Skip to main content
WeightCited

DHEA için Abdominal Fat Reduction

C Kanıt Küçük çalışmalardan sınırlı kanıt mevcuttur, ancak bazı olumlu sinyaller bulunmaktadır.

An 8-week RCT (n=45) found 7-Keto DHEA plus exercise produced greater weight loss (2.88 kg vs. 0.97 kg placebo). Meta-analysis in elderly found modest abdominal fat reduction. Long-term safety is unclear and DHEA is banned by WADA.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'weightcited.com'; const params = 'ingredient\u003Ddhea\u0026condition\u003Dabdominal\u002Dfat'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

Sonuç

An 8-week RCT (n=45) found 7-Keto DHEA plus exercise produced greater weight loss (2.88 kg vs. 0.97 kg placebo). Meta-analysis in elderly found modest abdominal fat reduction. Long-term safety is unclear and DHEA is banned by WADA.

Key Study Findings

Other n=60 7 weeks
Curcumin mitigates polycystic ovary syndrome in mice by suppressing TLR4/MyD88/NF-κB signaling pathway activation and reducing …
Dose: 200 mg/kg for 45 days vs: DHEA-induced PCOS model controls Outcome: PCOS attenuation via TLR4/MyD88/NF-kB pathway Etki: BW p=0.025, testosterone p=0.005 <0.05 multiple endpoints

Popülasyon: DHEA-induced PCOS C57BL/6J mice (4 groups, n=15)

In Vitro 3.0 weeks
Inulin and metformin ameliorate polycystic ovary syndrome via anti-inflammation and modulating gut microbiota in mice.
Dose: 4 g vs: Control Outcome: Gut microbiota composition Etki: None None

Popülasyon: None

Key Statistics

5

Çalışmalar

200

Katılımcılar

Positive

C

Derece

Referenced Papers

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Yaygın Kullanılan Dozajlar

general:
25-50 mg/day DHEA
guidance:
Guided by serum DHEA-S levels
7ketodhea:
100 mg 2x/day

Üst sınır: 50 mg/day for general use; higher doses under medical supervision only

Araştırmalarda İncelenen Dozajlar

Dozaj Süre Etki N
200 mg/kg for 45 days 7 weeks Positive 60
4 g 3.0 weeks Positive --

En iyi alım zamanı: Morning (mimics natural diurnal pattern)

Safety & Side Effects

Bildirilen Yan Etkiler

  • Acne
  • Hair loss
  • Facial hair growth (women)
  • Mood changes
  • Hormonal side effects

Bilinen Etkileşimler

  • Hormone-sensitive cancers (avoid)
  • Antiestrogens (may counteract)
  • Insulin and diabetes medications
  • WADA-banned in competitive sports

Tolere edilebilir üst alım: 50 mg/day for general use; higher doses under medical supervision only

Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.

Frequently Asked Questions

Does DHEA help with Abdominal Fat Reduction?
Based on 5 studies with 200 participants, there is limited but promising evidence that DHEA may support Abdominal Fat Reduction management. Our evidence grade is C (Some Evidence).
How much DHEA should I take for Abdominal Fat Reduction?
Studies have used various dosages. A commonly studied range is 25-50 mg/day DHEA. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of DHEA?
Reported side effects may include Acne, Hair loss, Facial hair growth (women), Mood changes. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for DHEA and Abdominal Fat Reduction?
We rate the evidence as Grade C (Some Evidence). This rating is based on 5 peer-reviewed studies with 200 total participants. The overall direction of effect is positive.

Şu durum için diğer içerikler: Abdominal Fat Reduction

References

  1. [1] Qin Yang et al.. Sci Rep. 2024. Curcumin mitigates polycystic ovary syndrome in mice by suppressing TLR4/MyD88/NF-κB signaling pathway activation and reducing intestinal mucosal permeability. doi:10.1038/s41598-024-81034-5 PubMed
  2. [2] Jing Xue et al.. Endocr J. 2019. Inulin and metformin ameliorate polycystic ovary syndrome via anti-inflammation and modulating gut microbiota in mice. doi:10.1507/endocrj.EJ18-0567 PubMed

FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.